ElectroCore has announced the commercial launch of gammaCore for the acute treatment of pain associated with episodic cluster headache in adult patients. GammaCore is a non-invasive, hand-held device which sends gentle electrical stimulation through the skin when applied to the neck. This activates the vagus nerve resulting in the reduction of pain.
The Food and Drug Administration (FDA) approved gammaCore in April after efficacy was demonstrated in two clinical trials involving over 200 patients with episodic cluster headaches (ACT1 and ACT2).
“We are proud to bring gammaCore to the U.S. market, as it provides episodic cluster headache sufferers with a much-needed treatment option for this rare and often debilitating condition,” said Francis R. Amato, CEO of electroCore.
GammaCore is available through prescription only, although patients may receive the device through a select group of headache centers around the country by enrolling in gammaCore Patient Registry (GPR); a non-research registry to assess the patient experience. In exchange for sharing information about their experiences using the device, patients will receive 2 months of gammaCore for no charge and co-pay assistance for up to 1 year, as part of the registry.
For more information visit gammaCore.com.